Fact Source: Financial Supervisory Service DART / 2025-02-25
Disclosure Type: Submission of Audit Report
💡 3-Second Summary
SAMSUNG BIOLOGICS has officially obtained an ‘Unmodified’ (clean) audit opinion from its external auditor (Samil PwC) for both consolidated and separate financial statements, validating its stellar FY2024 performance of KRW 4.55T in revenue and KRW 1.32T in operating profit.
📊 1. [Key Disclosure Content & Major Figures Summary]
- External Auditor: Samil PWC (Samil PricewaterhouseCoopers)
- Audit Opinion & Status:‘Unmodified’ for both consolidated and separate statements.
- Material Uncertainty Related to Going Concern: Not Applicable (None)
- Internal Accounting Control System Audit Opinion: Unmodified (No non-compliance issue)
- Embezzlement or Breach of Trust Cases Noted: None (No)
- FY2024 Consolidated Financial Metrics (Unit: KRW):
- Total Assets: KRW 17,336,296,349,511 (KRW 17.336T)
- Total Liabilities: KRW 6,431,620,287,493 (KRW 6.432T)
- Total Equity (Controlling Interest Same): KRW 10,904,676,062,018 (KRW 10.905T)
- Revenue: KRW 4,547,322,176,421 (KRW 4.547T, +23.08% YoY increase)
- Operating Profit: KRW 1,320,052,380,133 (KRW 1.320T, +18.53% YoY increase)
- Net Income: KRW 1,083,315,885,986 (KRW 1.083T, +26.31% YoY increase)
- FY2024 Separate Financial Metrics (Unit: KRW):
- Revenue: KRW 3,497,145,675,782 (KRW 3.497T)
- Operating Profit: KRW 1,321,425,521,850 (KRW 1.321T)
- Net Income: KRW 1,050,966,501,040 (KRW 1.051T)
- Structural Parameters: Number of consolidated subsidiaries remains at 14; major subsidiaries at 1. Total Equity to Capital Stock ratio climbed to 6,128.5% on a consolidated basis and 5,215.9% on a separate basis, reflecting a heavy acceleration in retained capital accumulation.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
The submission of the formal audit report is a milestone fundamental indicator confirming that the headline figures previously released in tentative reports have passed comprehensive statutory verification. For a bellwether biopharma giant, having an operating profit line of KRW 1.32T fully certified by a tier-one accounting firm like Samil PwC reinforces the supreme integrity of the corporate balance sheet.
From a structural safety standpoint, the disclosure indicates that potential governance or auditing risks are effectively zero. Regulatory flags such as going concern uncertanties, internal accounting deficiencies, or corporate malfeasance are completely cleared. Furthermore, watching the consolidated total equity cross the KRW 10.9T threshold—pushing the equity-to-capital ratio up to 6,128.5%—highlights immense internal cash retention capabilities. This solid capital foundation positions the firm beautifully to sustain aggressive, long-term capital expenditures (CAPEX) without leaning heavily on costly external financing.
Data validation confirms that the top-line revenue comfortably scales above the operating profit line, confirming layout alignment. Additionally, the tight equilibrium between standalone operating profit (KRW 1.321T) and consolidated operating profit (KRW 1.320T) reveals that subsidiaries are performing stably without acting as a drag on core profitability. While these metrics remain subject to formal sign-off at the upcoming general meeting of shareholders, the ‘Unmodified’ certified label means material revisions are highly unlikely, offering international institutional funds a highly reliable green light for steady inflows.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS’ FY2024 performance card has official crossed the finish line with an immaculate ‘Unmodified’ stamp from major auditors. The massive KRW 1.3T operating profit that turned heads during the initial tentative preview is now a legally certified corporate fact.
The standout takeaway here is the massive expansion of the equity-to-capital ratio past 6,100%. In the global CDMO arena, long-term success is dictated by a high-stakes race to build massive, highly regulated production facilities faster than the competition. Having this degree of internal capital retention provides management with an ultimate buffer to execute aggressive CAPEX expansions organically, bypassing high-interest debt traps. With accounting uncertainties completely neutralized, institutional macro players now have a rock-solid fundamental base to map out long-term utilization metrics and upcoming plant deployment schedules.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
